BCLI - BrainStorm announces data from its Phase 3 trial of NurOwn

2023-07-07 10:11:07 ET

• BrainStorm Cell Therapeutics ( NASDAQ: BCLI ) has presented new biomarker data from the Phase 3 trial of its late-stage investigational ALS treatment, NurOwn at the 2023 ALS and Related Motor Neuron Diseases Gordon Research Conference .
• These data show that treatment with NurOwn significantly elevated markers of neuroprotection and lowered markers of neuroinflammation and neurodegeneration, including neurofilament light over time compared to placebo in all trial participants.
• "The data we presented at the Gordon Research Conference show that it is equally important to examine biomarker data, particularly neurofilament light, which is a predictor of disease progression. Treatment-driven reductions in NfL are associated with better clinical outcomes in ALS." said Stacy Lindborg, PhD, BrainStorm co-CEO.

For further details see: